TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00861614

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ipilimumab
Description: 5 mg/ml solution, Intravenous, 10 mg/kg, Every 3 weeks for up to 4 doses in the Induction Phase. Every 12 weeks in the Maintenance Phase, Up to 24 weeks in Induction, 48+ weeks in the Maintenance Phase, or until Treatment Stopping Criteria are met, withdrawal of consent, lost to follow-up, death, study closure

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Solution, Intravenous, 0 mg, Every 3 weeks for up to 4 doses in the Induction Phase. Every 12 weeks in the Maintenance Phase, up to 24 weeks in Induction, 48+ weeks in the Maintenance Phase, or until Treatment Stopping Criteria are met, withdrawal of consent, lost to follow-up, death, study closure
Study: NCT03963661

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: c-SIGHT (computorized spatial innatention grasping home-based therapy)
Description: C-SIGHT will be self-administered at people's homes. c-SIGHT is a computerized therapy administered via people's television. The therapy involves performing repeated rod lifts with the less impaired arm in response to auditory and visual instructions presented on the television screen connected to a laptop. A small motion-tracking camera monitors rod lifts during therapy sessions. People will be asked to self-administer c-SIGHT for 1 hour a day (30min after breakfast and 30min after lunch) for 7 consecutive days. The first day of therapy will be performed with a therapist there for training purposes.
Study: NCT02687321

Intervention type: OTHER
Intervention: Determination of CA 125 and HE4, Computed tomography
Description: Blood sample collection to determinate tumor marker found in blood elevated by the presence of cancer recurrence.In case of one or both of tumor markers are elevated, computed tomography examination with intravenous contrast agent of chest and abdomen is performed to detect the recurrence of the disease.
Study: NCT00685321

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: H1 deep TMS coil
Description: 20 daily deep rTMS treatment

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham
Description: inactive treatment
Study: NCT00944658

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Apremilast
Description: 10mg twice a day, dose was titrated by 20mg every 2 days until the maximum dose 30mg twice a day for 12weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (sugar pill)
Description: twice a day
Study: NCT02452684

Intervention type: DRUG
Intervention: Eszopiclone
Description: The usual dosage of eszopiclone is 2 mg per dose for adults and 1 mg per dose for elderly participants, taken orally before bedtime. The dosage may be adjusted according to the participant's symptoms, but a single dose should not exceed 3 mg in adults and 2 mg in elderly participants.
Study: NCT01788345

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: non- invasive ventilation
Description: non-invasive bi-level ventilation with IPAP and EPAP.
Study: NCT03554993

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CC-99677
Description: CC-99677

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CC-99677
Description: CC-99677

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo
Study: NCT03221010

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivational Interviewing
Description: Motivational Interview (MI) is a person-centered, communicative method whose purpose is to work and increase the user's motivation for behavior change.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Traditional cognitive-behavioral approach
Description: This approach aims to combine cognitive interventions in the training of behavioral skills in patients, developing strategies to cope with the problem and detecting situations of risk, mobilizing the subject for his own process of change. Helps correct cognitive dysfunctions and behavioral changes in specific situations.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Traditional cognitive-behavioral approach
Description: This approach aims to combine cognitive interventions in the training of behavioral skills in patients, developing strategies to cope with the problem and detecting situations of risk, mobilizing the subject for his own process of change. Helps correct cognitive dysfunctions and behavioral changes in specific situations.
Study: NCT02111785

Intervention type: DRUG
Group type: OTHER
Intervention: Dexamethasone
Description: Treatment with a short course of oral dexamethasone

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Treatment with a short course of oral dexamethasone
Study: NCT00764374

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YM443
Description: oral
Study: NCT04354766

Intervention type: OTHER
Intervention: Blood sample
Description: This study will require a blood sample (4 ACD tubes, 20 ml) at one time.

Intervention type: OTHER
Intervention: Blood sample
Description: This study will require a blood sample (4 ACD tubes, 20 ml) at one time.
Study: NCT01789996

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: alternative six minute walk test
Description: Alternate instructions will be given Subjects will~1. walk as fast as they can in 6 minutes~2. walk as normally as they can in 6 minutes~3. walk leisurely as they can in 6 minutes. Pts will serve as their own controls.

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Standard six minute walk test
Description: Subjects will walk as far as they can in 6 minutes
Study: NCT00199498

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Apical RV lead placement
Description: RV lead implanted ( according to randomization )at the apex

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Septal RV lead placement
Description: RV lead is implanted (according to randomization), on septum
Study: NCT00750100

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: human chorionic gonadotropin
Description: hCG 200IU in the late follicular phase

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: recombinant gonadotropins
Description: 200 IU per day during controlled ovarian stimulation
Study: NCT02235467

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: ABA parent training
Description: A parent training based on Applied Behavior Analysis that is going to be delivered by video modeling in 21 weeks
Study: NCT02357290

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Open-label Treatment with N-Acetylcysteine
Study: NCT04243460

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Xenogeneic collagen matrix (XCM) graft augmentation
Description: 12 months after gingival augmentation Measurement of marginal bone level and soft tissue thickness were done. STT (soft tissue thickness) was measured using ultrasonography with a Pirop® dental, ultrasound device (Echoson Company, Poland). The patients underwent a clinical and ultrasound examination before, 3 and 12 months after gingival augmentation (GA) respectively to evaluate TKT at two points using ultrasound equipment (Pirop®, Echoson).~Intraoral radiographs were taken using a paralleling technique with a Rinn-type film holder in high resolution mode (Visualixe HD®, Gendex®, USA). Two images of each region were selected to calculate the marginal bone changes:

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Connective tissue graft augmentation (CTG)
Description: 12 months after gingival augmentation Measurement of marginal bone level and soft tissue thickness were done. STT (soft tissue thickness) was measured using ultrasonography with a Pirop® dental, ultrasound device (Echoson Company, Poland). The patients underwent a clinical and ultrasound examination before, 3 and 12 months after gingival augmentation (GA) respectively to evaluate STT (soft tissue thickness) at two points using ultrasound equipment (Pirop®, Echoson).
Study: NCT02254408

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Presatovir
Description: Presatovir 200 mg (4 × 50 mg tablets) administered orally or via nasogastric (NG) tube

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Tablets administered orally or via nasogastric tube
Study: NCT03766841

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Facilitated Enrollment
Description: Research coordinator will assist patients in account creation and usage of the tool.
Study: NCT02176044

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sodium Nitroprusside infusion

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT02410967

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Attention Bias Modification
Description: At each of eight sessions, participants complete 160 computer administered trials wherein a pair of threatening stimuli and neutral stimuli is presented simultaneously and then followed immediately by a probe. The probe always replaces the neutral stimulus and never replaces the threatening stimulus. The intervention is based on the idea that attention can be shaped via repetitive computer based training methods, and training attention toward neutral stimuli will lead to a reduction in anxiety and its disorders.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Attention Task
Description: At each of eight sessions, participants complete 160 computer administered trials wherein a pair of threatening stimuli and neutral stimuli is presented simultaneously and then followed immediately by a probe. The probe replaces the neutral stimulus and the threatening stimulus with equal probability.
Study: NCT03202472

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Implanted Medical Device
Description: Radiofrequency tag

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Mammography
Description: Undergo mammogram for image-guided placement of radiofrequency tag

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Radiofrequency (RFID) -Guided Localization
Description: Undergo radiofrequency-guided localization

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ultrasonography
Description: Undergo ultrasound for image-guided placement of radiofrequency tag
Study: NCT01057030

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BMS-708163
Description: Capsules, Oral, 125 mg, once daily, 14 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BMS-708163
Description: Capsules, Oral, 125 mg, once daily, 14 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Capsules, Oral, 0 mg, once daily, 14 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Capsules, Oral, 0 mg, once daily, 14 days
Study: NCT03815084

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pd-1 and DC-NK cells
Description: total dose of 10ml KEYTRUDA® (pembrolizumab) will be administered at day0, 60million DC cells and 3 billion NK at day1, 3 billion NK cells at day2, 3 billion NK cells at day3 .
Study: NCT03040882

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: cotton sock
Description: Application of a cotton sock in the immediate postoperative period before applied the Walker

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Elastic Compression Wraps
Description: Application of an Elastic Compression Wraps in the lower limb in the immediate postoperative period before applied the Walker (standard care)
Study: NCT00487734

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Testosterone gel
Description: testosterone gel, applied daily. Dosed to achieve testosterone level \<500 ng/dL. Possible doses include 2.5g, 5g, 7.5g or 10g gel packets.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for testosterone gel
Description: Placebo gel, 2.5g for each gel packet
Study: NCT01048645

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ATRA
Description: Patients were assigned to receive ATRA 20 mg/m2/day (RA/PC) 1 week prior to treatment until completing two courses of chemotherapy based on paclitaxel and cisplatin

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: PLACEBO
Description: Patients were randomized to receive or placebo (P/PC) 1 week prior to treatment until completing two courses of chemotherapy based on paclitaxel and cisplatin
Study: NCT01993017

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT)
Description: The main intervention is the impact of screening on quality of life and health care costs. CBT is provided only if depressive symptoms are detected and participant prefers this type of treatment.~CBT will be centrally telephone-administered by a trained CBT treatment specialist. The treatment specialist will work with local team members throughout a participant's involvement in the study, and will closely follow each participant until he or she has reached a requisite level of improvement .

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antidepressant Medication
Description: The main intervention is the impact of screening on quality of life and health care costs. Antidepressant Medication is provided only if depressive symptoms are detected and patient prefers this type of treatment.~Antidepressants should be started at the lowest dose, but should be adjusted upward to be within the therapeutic range within 1 week, with further adjustment higher in the therapeutic range possible at 3-4 weeks. Dosage of the first medication selected will be in the therapeutic range by 3 weeks of the initial step, as tolerated.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard Care
Description: Participants will receive standard care from either their primary care provider (PCP), or PCP-referred mental health provider in one of the arms, IF depressive symptoms are detected.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Depressive symptom screener
Description: 8-item Patient Health Questionnaire, PHQ-8

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Depressive symptom screener
Description: 8-item Patient Health Questionnaire, PHQ-8

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: No intervention
Study: NCT00811447

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-fluorouracil
Description: 600 mg/m²/day intravenous

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 5-fluorouracil
Description: 600 mg/m²/day intravenous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: 60 mg/m² or 75 mg/m² intravenous

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin
Description: 60 mg/m² or 75 mg/m² intravenous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: 60 mg/m² intravenous
Study: NCT01240954

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: OSIRIS
Description: OSIRIS current practice

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OSIRIS other concentration 1
Description: OSIRIS new concentration 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OSIRIS other concentration 2
Description: OSIRIS new concentration 2
Study: NCT00694382

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Semuloparin sodium
Description: 0.4 mL solution in ready-to-use 0.5 ml pre-filled syringe~Subcutaneous injection

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (for semuloparin)
Description: 0.4 mL solution in ready-to-use 0.5 ml prefilled syringe strictly identical in appearance but without active component~Subcutaneous injection
Study: NCT06089252

Intervention type: DRUG
Group type: OTHER
Intervention: walnut extract
Description: Four times a day over a 10-day period
Study: NCT04463121

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Moderato IPG's CNT pacing signals
Description: Assesment of cardiac function and sympatheric activity will be obtained simultaneously

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CD Leycom Pressure/Volume Combination Catheters
Description: Simultaneous recording of the Pressure, Volume measurements and ECG signals will be done for constant monitoring of intra-ventricular pressure and volume.
Study: NCT02584348

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Gastric ultrasound
Description: Preoperative qualitative ultrasound assessment of gastric contents will be performed for each children admitted for emergency surgery
Study: NCT04328402

Intervention type: DIAGNOSTIC_TEST
Intervention: Polysomnography
Description: Polysomnography, referred to as type I, allows assessing several sleep physiologic parameters (eg, EEG, electrooculogram, electromyogram, electrocardiogram, airflow, respiratory effort, oxygen saturation), whereas audio-video recording enables to document tooth-grinding sounds and distinguishing between rhythmic masticatory muscle activity (RMMA) and orofacial and other muscular activity during sleep. The apnea and hypopnea index (AHI) is defined as the number of obstructive apneas and hypopneas per hour of sleep. Obstructive Sleep Apnea is defined in PSG when AHI≥1 and is divided into the following categories, according to severity: mild OSA (AHI 1-4.9), moderate OSA (AHI 5-9.9) and severe OSA (IAH≥10). Based on the RMMA index (number of episodes per hour of sleep), sleep bruxism is diagnosed when episodes are greater than or equal to 2 (low-frequency SB, mild bruxism) or episodes are greater than or equal to 4 (high frequency SB, severe bruxism).
Study: NCT01396577

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: perampanel
Description: 3 x 2 mg perampanel once per day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: perampanel
Description: 6 mg perampanel once per day
Study: NCT03117725

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melatonin adminstration
Description: The drug, melatonin will be taken every night from the time of COH to the date of oocyte retrieval. The method of administration is as follows: Melatonin 2mg once a day, 1 to 2 hours before bedtime for about 2 weeks until the date of oocyte retrieval.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo administration
Description: the drug, placebo pill will be taken every night from the time of COH to the date of oocyte retrieval. The method of administration is as follows: placebo pill once a day, 1 to 2 hours before bedtime for about 2 weeks until the date of oocyte retrieval.
Study: NCT03899961

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxytocin
Description: Oxytocin 2.5 U i.v.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carbetocin
Description: Carbetocin 100 µg i.v.
Study: NCT03013218

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Evorpacept (ALX148)
Description: Evorpacept (ALX148)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Evorpacept (ALX148)
Description: Evorpacept (ALX148)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Evorpacept (ALX148)
Description: Evorpacept (ALX148)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Evorpacept (ALX148)
Description: Evorpacept (ALX148)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Evorpacept (ALX148)
Description: Evorpacept (ALX148)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Evorpacept (ALX148)
Description: Evorpacept (ALX148)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Keytruda

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Keytruda

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Description: Herceptin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Description: Herceptin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Rituxan

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ramucirumab + Paclitaxel
Description: Standard of care chemotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-FU + Cisplatin
Description: Standard of care chemotherapy
Study: NCT03913208

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Priority to freeze
Description: Priority for cryopreservation and later on embryo transfer in artificial cycle with endometrium preparation by the exogenous administration of estrogen-progesterone.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Fresh embryo transfer
Description: usual strategy of giving the priority for fresh embryo transfer
Study: NCT03779178

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Landiolol
Description: Landiolol perfusion over 120 minutes in incremental doses : 0.5, 1, 2, 5 and 10 µg/kg/min. Doses are modified every 20 minutes

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo perfusion is sodium chloride NaCl 0.9% over 120 minutes in incremental doses : 0.03, 0.06, 0.12, 0.3 and 0.6 mL/kg/h. Doses are modified every 20 minutes. Perfusion are similar in landiolol group to preserve blind.
Study: NCT02057601

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levobupivacaine infiltration group
Description: The patients in the intervention group will receive peri-surgical site infiltration before wound closure with a solution of levobupivacaine 0.5% 2mg/kg body weight with epinephrine made up to a volume of 1.5ml/kg with saline.
Study: NCT00939731

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-02341066
Description: A 250-mg single dose of PF-02341066 administered as 1 x 50-mg Powder-in-Capsule and 2 x 100-mg Powder-in-Capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-02341066
Description: A 250-mg single dose of PF-02341066 administered as 1 x 50-mg Immediate Release Tablet and 2 x 100-mg Immediate Release Tablets
Study: NCT03634501

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Activated NK
Description: Cell suspension
Study: NCT01047644

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Reduced port-flush schedule
Description: 3-month port-flushing
Study: NCT01861821

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Multiport flexible catheter
Description: Multiport flexible catheter has three ports for the delivery of epidural medication

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Uniport flexible catheter
Description: Uniport flexible catheter has one port for the delivery of epidural medication
Study: NCT01042743

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: robot-assisted surgery
Description: da Vinci surgical system® (Intuitive Surgical, Sunnyvale, CA, USA)

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: laparoscopic right-hemicolectomy
Description: Conventional laparoscopic procedures